Skip to main
GPCR

GPCR Stock Forecast & Price Target

GPCR Analyst Ratings

Based on 12 analyst ratings
Strong Buy
Strong Buy 58%
Buy 42%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Structure Therapeutics is poised for success with their promising weight loss drug, aleniglipron, and the upcoming FDA End-of-Phase-2 meeting in 2026 is a key milestone. The company's focus on dose selection, comparator requirements, and cardiovascular outcomes trial timing for their oral GLP-1s demonstrates their dedication to delivering safe and effective treatments for chronic diseases. The recent acquisitions of Carmot and Eccogene have bolstered their capabilities and made them an attractive target for acquisition in the competitive obesity market.

Bears say

Structure Therapeutics is a clinical stage biopharmaceutical company with a pipeline of small-molecule therapeutics aimed at treating chronic diseases. With promising Phase 2 data for its lead drug, aleniglipron, and a novel oral amylin program in development, there is increased interest and potential for significant return for investors. However, there are potential risks, such as failure in clinical studies or competition in the overcrowded obesity market, that could impact the company's success. Additionally, while potential for acquisition by larger pharma companies exists, it is uncertain who the potential acquirer would be at this time.

GPCR has been analyzed by 12 analysts, with a consensus rating of Strong Buy. 58% of analysts recommend a Strong Buy, 42% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Structure Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Structure Therapeutics Inc (GPCR) Forecast

Analysts have given GPCR a Strong Buy based on their latest research and market trends.

According to 12 analysts, GPCR has a Strong Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $104.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $104.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Structure Therapeutics Inc (GPCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.